On November 6, 2018 CytomX Therapeutics, Inc. (Nasdaq: CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that clinical translational data from PROCLAIM-CX-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, will be presented as a poster and in a rapid fire oral presentation at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, CytomX Therapeutics, NOV 6, 2018, View Source [SID1234530788]). The conference will take place from November 7-11, 2018 in Washington, DC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster P87: Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2a Trial
Presenter: Luc Desnoyers, Ph.D., Senior Director of Translational Sciences, CytomX Therapeutics
Date/Time: November 9, 2018; 8:00 – 9:00 a.m. /12:45 – 2:45 p.m. /6:30 – 8:00 p.m. EST
Location: Poster Hall E, Walter E. Washington Convention Center
Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2a Trial
Presenter: Luc Desnoyers, Ph.D., Senior Director of Translational Sciences, CytomX Therapeutics
Session: Rapid Oral Abstracts
Date/ Time: November 10, 2018; 1:05 – 1:10 p.m. EST
Location: Poster Hall E, Walter E. Washington Convention Center
Analyst and Investor Event and Webcast
CytomX will host an Analyst and Investor event on Saturday, November 10, 2018 from 12:30 to 2:00 p.m. EST to review the SITC (Free SITC Whitepaper) clinical data presentation. Participants are invited to listen to a live audio webcast of the presentation at View Source or by dialing 1-877-809-6037 or 1-615-247-0221 and using code 4597498. The event will also be available for replay for 30 days on the company’s website, www.CytomX.com.
For analysts and investors interested in attending the event in person, please contact [email protected] as space is limited.